News | January 26, 2022
Cipla’s Q3FY22 PAT at Rs 729 cr.
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
_256_384.jpg)
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
The six-layer packaging ensures that external media such as bacteria, light and air do not contaminate the liquid
Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas
Narayanan to lead SeQuent through next phase of consolidation and growth
The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
10 implementation focused initiatives recommended to accelerate policy reforms, standardization of home care delivery services, and improve accessibility and affordability of care in tier II and tier III geographies
Rapid antigen testing provides results in just 15 minutes and the information can help reduce the risk of Covid-19 exposure
G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE
Subscribe To Our Newsletter & Stay Updated
